Attila Szabo
Researcher in psychoneuroimmunology and psychedelic science; affiliated with the University of Oslo
Papers
11 publications
Trials
0 clinical trials
Key Impact
He is a notable contributor to psychedelic immunology research, including widely cited work on DMT, 5-MeO-DMT, psilocybin, and immune modulation.
Background & Research
Attila Szabo has published on the immune and neuroprotective effects of psychedelics, especially DMT, 5-MeO-DMT, and psilocybin. His papers link psychedelic compounds to sigma-1 receptor biology, inflammatory signaling, and psychoneuroimmunology. Recent publication metadata indicates an affiliation with the University of Oslo. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/25171370/?utm_source=openai))
Collaboration Network
19 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Immunology & InflammationDepressive DisordersSubstance Use Disorders (SUD)Anxiety DisordersSchizophreniaNeurocognitive DisordersHealthy VolunteersMajor Depressive Disorder (MDD)Bipolar DisorderPTSDNeuroimaging & Brain MeasuresMedicinal Chemistry & Drug DevelopmentPalliative & End-of-Life DistressNeurological Injury